On Wednesday, Shares of Navios Maritime Acquisition Corporation (NYSE:NNA), gained 0.27% to $3.75.
Navios Maritime Acquisition Corporation, declared that the Nave Neutrino, a 2003-built VLCC, has been chartered out to a high quality counterparty for two years at an average rate of $40,500 net per day with the first and last month of the contract being priced on the BITR TD3-TCE index. The vessel is predictable to generate about $20.9 million of base EBITDA for the period of this charter assuming operating expense approximating current operating costs.
Navios Maritime Acquisition Corporation provides marine transportation services worldwide. The company owns a fleet of crude oil, refined petroleum product, and chemical tankers.
Shares of Keysight Technologies Inc (NYSE:KEYS), inclined 1.82% to $33.55, during its last trading session.
Keysight Technologies, declared it is collaborating with the University of Bristol on 5G millimeter-wave research. The two organizations are already deeply involved in the 5G ecosystem in Europe and the U.S. and now will be working closely together on multiple 5G millimeter-wave technologies.
The pursuit of more bandwidth for ever-faster digital wireless communications has pushed the research community to explore how to use much higher frequencies for commercial mobile multiple-access performance. The partnershipcombines Bristol’s leading-edge wireless research with Keysight’s deep experience and capability in millimeter-wave and ultra-broadband simulation, design, test and measurement. The work will contribute to the development of the new capabilities needed for 5G and at the same time enable a richer mutual learning environment for Keysight and the researchers at the University of Bristol.
Keysight Technologies, Inc. provides electronic measurement solutions to the communications and electronics industries in the United States and internationally. It operates through two segments: Measurement Solutions, and Customer Support and Services.
At the end of Wednesday’s trade, Shares of Dolby Laboratories, Inc. (NYSE:DLB), gained 2.52 % to $32.53.
Dolby Laboratories, declared five new Hollywood features, counting the first two titles from Twentieth Century Fox, will be joining the Dolby Cinema experience. Dolby Cinema, featuring Dolby Vision and Dolby Atmos, is a premium cinema offering for exhibitors and moviegoers that combines spectacular image and sound technologies with inspired design to make every visit a completely captivating cinematic event.
The Sony Pictures title The Perfect Guy, in theatres September 11; Twentieth Century Fox’s Maze Runner: The Scorch Trials, in theatres September 18; and The Martian, in theatres October 2; followed by the Warner Bros. Pictures title Pan, in theatres October 9, and In the Heart of the Sea (Village Roadshow Pictures), in theatres December 11, will deliver a sense of fear, adrenaline, and fun when practiced at a Dolby Cinema location.
“We are delighted to see a dynamic slate of movies, with all the major Hollywood studios embracing recently’s most advanced and powerful imaging and sound technologies,” said Doug Darrow, Senior Vice President, Cinema, Dolby Laboratories. “Dolby Cinema has demonstrated that it can transport the audience into a new world of action-packed blockbusters with booming sounds, but can also pack animated films with heart and emotion.”
Dolby Laboratories, Inc. creates audio, imaging, and communication technologies that transform entertainment and communications at the cinema, at home, at work, and on mobile devices.
Finally, Verastem Inc (NASDAQ:VSTM), ended its last trade with -0.63% loss, and closed at $6.33.
Verastem, declared that the company will present at the Rodman and Renshaw 17th Annual Global Investment Conference on Thursday, September 10 at 3:50 p.m. ET at the St. Regis Hotel in New York City.
Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs). The company’s programs target the focal adhesion kinase (FAK) and the PI3K/mTOR signaling pathways. Its lead FAK inhibitor, VS-6063, is in a registration-directed trial in patients with malignant pleural mesothelioma; a Phase Ib trial in combination with weekly paclitaxel for patients with ovarian cancer; a Phase II study in patients with non-small cell lung cancer; and a Phase II trial preceding surgery in mesothelioma, in addition to a combination trial of VS-6063 and VS-5584 in patients with relapsed mesothelioma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
